SCHEMBL6134960

SCHEMBL6134960

CCOC(=O)c1cccc(Oc2ccc3c(c2)C[C@@H](N(C[C@H](O)c2cccnc2)C(=O)OC(C)(C)C)CC3)c1

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 15/20 0.53
ADRB1 P08588 8/20 0.40
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134961 1.00 ADRB3 (0.53) ADRB3ADRB1KDM4EALDH1A1
SCHEMBL6133668 0.91 ADRB3 (0.64) ADRB3ADRB1
SCHEMBL6133670 0.91 ADRB3 (0.64) ADRB3ADRB1
SCHEMBL6133709 0.89 ADRB3 (0.43) ADRB3ADRB1
SCHEMBL6133712 0.89 ADRB3 (0.43) ADRB3ADRB1
SCHEMBL6134814 0.89 ADRB3 (0.54) ADRB3ADRB1
SCHEMBL6134816 0.89 ADRB3 (0.54) ADRB3ADRB1
SCHEMBL6134469 0.88 ADRB3 (0.51) ADRB3ADRB1
SCHEMBL6134472 0.88 ADRB3 (0.51) ADRB3ADRB1
SCHEMBL6134801 0.87 ADRB3 (0.44) ADRB3ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090669-A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists ASTELLAS PHARMA INC. (JP) 2005-04-28 US disclosed
EP-1483236-A1 AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-08 EP disclosed
WO-2003076397-A1 AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090669-A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists ADRB2, ADRB1, ADRB3 ADRB3 3/4885ADRB1 2/4885KDM4E 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.